| OHSU # 3286 |
CD74 as a biomarker and therapeutic target for familial platelet (FPD) disorder |
Anupriya Agarwal, Mona Mohammadhosseini |
| OHSU # 3234 |
Combination therapy for the treatment of triple negative breast cancer |
Sanjay Malhotra, Lisa Coussens, Dhanir Tailor, Sushil Kumar, Arpit Dheeraj |
| OHSU # 3147 |
Malaria transmission blocking using ELQ-infused bed nets |
Michael Riscoe, Aaron Nilsen, Joseph (Stone) Doggett, Flaminia Catteruccia, Douglas (Doug) Paton |
| OHSU # 3063 |
A method of enhancing cancer immunotherapies through androgen receptor modulation |
Fanny Polesso, Amy Moran |
| OHSU # 3024 |
Universal nanoprobes for imaging and treatment of cancer |
Adem Yildirim, Jared Fischer, Bruce Branchaud |
| OHSU # 3015 |
Covalent inhibitors of PARP-16 for cancer treatment |
Michael (Mike) Cohen, Daniel Bejan, Sunil Sundalam |
| OHSU # 3001 |
Anti-cancer compounds with improved cardiac safety and drug resistance profiles |
Mark Mercola, Sanjay Malhotra, Mallesh Pandrala, Dhanir Tailor, Arne Antoon Bruyneel |
| OHSU # 2939 |
Photoactivatable modulation of antibody binding |
Stuart Ibsen, Michael Brasino |
| OHSU # 2823 |
Nanoparticle ultrasound contrast agents with high acoustic activity |
Adem Yildirim, Jose Luis Montoya Mira, Sadik Esener, Stuart Ibsen |
| OHSU # 2779 |
Novel agents for the detection and treatment of bladder cancer |
John Muschler |
| OHSU # 2757 |
Clickable, photoactivatable NAD+ analogues as probes for PARP and other NAD+-binding targets |
Sunil Sundalam, Michael (Mike) Cohen |
| OHSU # 2750 |
Compositions for treatment of neurological and oxidative stress disorders |
Michael (Mike) Cohen, Michael Forte, Justina Sileikyte, Jordan Devereaux, Aaron Nilsen, Paolo Bernardi |
| OHSU # 2670 |
Inhibitors of cancer-mediated bone destruction |
Raymond Bergan, Ryan Gordon, Abhinandan Pattanayak |
| OHSU # 2648 |
Methods of treating venetoclax-resistant acute myeloid leukemia |
Jeffrey (Jeff) Tyner, Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Shannon McWeeney, Stephen (Steve) Kurtz, Christopher (Chris) Eide, Ravindra Majeti |
| OHSU # 2561 |
Mutation-specific treatment strategies for acute myeloid leukemia |
Jeffrey (Jeff) Tyner, Cristina Tognon, Brian Druker, Daniel Bottomly, Beth Wilmot, Stephen (Steve) Kurtz, Samantha Savage Stevens, Nicola Long, Anna Reister Schultz, Elie Traer, Shannon McWeeney |
| OHSU # 2533 |
Adaptive exercise-enabled model-predictive-control artificial pancreas control algorithm |
Peter Jacobs, Joseph Leitschuh, Jessica Castle, Joseph El Youssef, Seyed (Navid) Resalat, Ravi Reddy |
| OHSU # 2526 |
Adaptive exercise-enabled proportional-derivative artificial pancreas control algorithm |
Peter Jacobs, Joseph Leitschuh, Jessica Castle, Joseph El Youssef, Seyed (Navid) Resalat, Ravi Reddy |
| OHSU # 2165 |
Compounds that bind macrophage migration inhibitory factor |
Arthur Vandenbark, Gil Benedek, Roberto Meza-Romero |
| OHSU # 2044 |
Oligonucleotides for long QT syndrome |
Zhengfeng Zhou, Qiuming Gong, Matthew Stump |
| OHSU # 1967 |
Small molecule inhibitors of the mitochondrial permeability transition pore (PTP) |
Michael Forte, Dennis Bourdette, Paolo Bernardi, Justina Sileikyte, Frank Schoenen, Sudeshna Roy |
| OHSU # 1838 |
Method of producing human pluripotent stem cells by somatic cell nuclear transfer |
Shoukhrat Mitalipov, Masahito Tachibana |
| OHSU # 1688 |
Cloroquine replacement drugs |
Michael Riscoe, Rolf Winter, Sovitj Pou, David Hinrichs, Jane Kelly, Yuexin Li, Aaron Nilsen |
| OHSU # 1295 |
Naphthamides as anticancer agents inhibiting CREB-mediated gene transcription |
Xiangshu Xiao, Bingbing Li |